Conditions: Age Related Macular Degeneration Cognition Disorders
Keywords: Macular Pigment Optical Density Skin Carotenoids Lipofuscin Photostress (Glare Recovery) Visual Field Progression Contrast Sensitivity Color Vision Cognitive Function
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: no

Brief summary:
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.

Detailed description:
To evaluate whether or not zeaxanthin supplementation raises macular pigment optical density (MPOD). Previous research has shown MPOD to mirror visual benefits for patients with age related atrophic macular degeneration (AMD) having visual symptoms (decreased visual acuity, contrast sensitivity, photostress glare recovery and National Eye Institute Visual Function Questionnaire 25 scores), but lower risk National Eye Institute (NEI) / Age Related Eye Disease Study (AREDS) characteristics.

Arms:
arm 1: 9 mg of Lutein for 12 months arm 2: 3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months arm 3: 3R 3'R Zeaxanthin 8 mg per day during 12 months

Interventions: intervention 1: 3R 3'R Zeaxanthin intervention 2: Lutein intervention 3: Lutein and Zeaxanthin
Intervention descriptions: intervention 1: 8 mg per day during 12 months intervention 2: 9 mg of Lutein during 12 months intervention 3: 8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months

Protocol document: